ArticleCancers2022
Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Prognostic value of platelet to lymphocyte ratio (PLR) in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- The prognostic value of absolute lymphocyte count and neutrophil-to-lymphocyte ratio for patients with metastatic breast cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Clinical utility of the pan-immune-inflammation value in breast cancer patients.Frontiers in oncology · 2023Pooled it
- Dynamic Assessment of Systemic Inflammatory Markers in Predicting Pathological Complete Response After Neoadjuvant Treatment in Triple-Negative Breast Cancer.Journal of clinical medicine · 2026Article
- Investigation of pan-immune inflammatory value in patients with age-related macular degeneration.BMC ophthalmology · 2026Article
- Pan-immune-inflammation value: racial variations and differences in prognostic accuracy across breast cancer subtypes at a single institution.Frontiers in oncology · 2026Article
- Risk factors for dyseugia during chemotherapy in breast cancer women: A cohort STROBE-guided.Journal of clinical and experimental dentistry · 2026Review
- Leukocyte Ratios Predict Metastasis, Recurrence, and Mortality in Breast Cancer Patients Receiving Cytotoxic Chemotherapy.Medical sciences (Basel, Switzerland) · 2025Observational
- Nomogram predictive model for the incidence and risk factors of persistent fever after cardiovascular surgery.BMC surgery · 2025Article
- Evaluation of serum alkaline phosphatase and lactate dehydrogenase as predictive biomarkers for the prognosis of male breast cancer.Scientific reports · 2025Article
- PIV and PILE scores predict the clinical outcome in patients with metastatic breast cancer treated with CDK4/6 inhibitors.International journal of clinical oncology · 2025Article
- Predictive and Prognostic Value of Inflammatory and Nutritional Indexes in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy.Medicina (Kaunas, Lithuania) · 2024Article
- Albumin-To-Alkaline Phosphatase Ratio as a New Early Predictive Marker of Axillary Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Pilot Study.Medicina (Kaunas, Lithuania) · 2024Article
- Prognostic role of dynamic changes in inflammatory indicators in patients with non-small cell lung cancer treated with immune checkpoint inhibitors-a retrospective cohort study.Translational lung cancer research · 2024Article
- The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy.Scientific reports · 2024Article
- Limited value of platelet-related markers in diagnosing periprosthetic joint infection.BMC musculoskeletal disorders · 2024Article
- Predictive value of pre-operative prognostic nutritional index and systemic immune-inflammation index for efficacy and survival in patients with non-small cell lung cancer undergoing neoadjuvant chemotherapy.American journal of translational research · 2024Article
- Prognostic value of immune-inflammatory and nutrition indicators in non-metastatic nasopharyngeal carcinoma with negative plasma Epstein-Barr virus DNA.Therapeutic advances in medical oncology · 2024Article
- Preoperative prognostic nutritional index and systemic immune inflammation index for predicting the efficacy and survival time of patients with osteosarcoma undergoing neoadjuvant chemotherapy combined with surgery.American journal of cancer research · 2024Article
- Development of a nomogram for predicting survival of breast cancer patients with neoadjuvant chemotherapy: a dynamic analysis for systemic inflammation response index.Gland surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune inflammatory biomarkers are easily obtained and inexpensive blood-based parameters that recently showed prognostic and predictive value in many solid tumors. In this study, we aimed to investigate the role of these biomarkers in predicting distant relapse in breast cancer patients treated with neoadjuvant chemotherapy (NACT). All breast cancer patients who referred to our Breast Unit and underwent NACT were retrospectively reviewed. The pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and pan-immune-inflammation value (PIV) were calculated from complete blood counts. The primary outcome was 5-year distant-metastasis-free survival (DMFS). In receiver operating characteristic analyses, the optimal cutoff values for the NLR, PLR, MLR, and PIV were determined at 2.25, 152.46, 0.25, and 438.68, respectively. High levels of the MLR, but not the NLR, PLR, or PIV, were associated with improved 5-year DMSF in the study population using both univariate (HR 0.52,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.